Wednesday - November 19, 2025

Aprea Therapeutics (Nasdaq: APRE) Advances Cancer Pipeline as Maxim Group Sets $10 Price Target

Aprea Therapeutics (Nasdaq: APRE) a clinical-stage oncology company developing next-generation cancer therapies — reported strong third-quarter progress as its lead drug programs continue to show encouraging clinical activity in multiple genetically driven cancers. The company’s precision-oncology approach targets defects in … Continue reading

The New Era of Treasury Strategy: ENDRA Life Sciences (NASDAQ: NDRA) Impacting Healthcare

ENDRA Life Sciences (NASDAQ: NDRA), a pioneer in next-generation medical imaging for the early detection and monitoring of liver disease, is redefining strategic finance for public companies through an innovative treasury management program that enhances liquidity, financial stability, and long-term … Continue reading